Caribou Biosciences (NASDAQ:CRBU) Rating Lowered to Sell at Wall Street Zen

Key Points

• Wall Street Zen has downgraded Caribou Biosciences (NASDAQ:CRBU) from a "hold" rating to a "sell" rating.
• HC Wainwright reiterated a "buy" rating with a target price of $3.00, down from a previous target of $9.00.
• Recent trading data shows Caribou Biosciences opened at $1.98 and has a market cap of approximately $184.38 million.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $6.67.

Caribou Biosciences Price Performance

Shares of NASDAQ CRBU traded up $0.03 during trading on Friday, reaching $1.80. 473,225 shares of the stock traded hands, compared to its average volume of 1,474,964. Caribou Biosciences has a 52-week low of $0.66 and a 52-week high of $2.9995. The company has a 50-day moving average of $1.70 and a 200-day moving average of $1.26. The stock has a market capitalization of $167.62 million, a P/E ratio of -1.01 and a beta of 2.55.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05. The firm had revenue of $2.67 million for the quarter, compared to analysts' expectations of $1.64 million. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%. Analysts expect that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CRBU. JPMorgan Chase & Co. boosted its holdings in Caribou Biosciences by 475.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock valued at $3,969,000 after purchasing an additional 2,062,563 shares during the period. Wells Fargo & Company MN boosted its holdings in Caribou Biosciences by 112.8% in the 4th quarter. Wells Fargo & Company MN now owns 91,988 shares of the company's stock valued at $146,000 after purchasing an additional 48,759 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Caribou Biosciences by 43.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 46,301 shares of the company's stock valued at $74,000 after purchasing an additional 14,021 shares during the period. Russell Investments Group Ltd. boosted its holdings in Caribou Biosciences by 859.0% in the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock valued at $38,000 after purchasing an additional 21,416 shares during the period. Finally, Barclays PLC boosted its holdings in Caribou Biosciences by 12.0% in the 4th quarter. Barclays PLC now owns 145,417 shares of the company's stock valued at $231,000 after purchasing an additional 15,578 shares during the period. 77.51% of the stock is owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.